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Abstract
The use of neutralizing antibodies is one of the most successful methods to interfere with receptor-ligand interactions in vivo.
In particular blockade of soluble inﬂammatory mediators or their corresponding cellular receptorswas proven an effective way
to regulate inﬂammation and/or prevent its negative consequences. However, one problem that comes along with an effective
neutralization of inﬂammatory mediators is the general systemic immunomodulatory effect. It is therefore important to design
a treatment regimen in a way to strike at the right place and at the right time in order to achieve maximal effects with minimal
duration of immunosuppression or hyperactivation. In this review wereﬂect on two examples of howshorttime administration
of such neutralizing antibodies can block two distinct inﬂammatory consequences of viral infection. First, we review recent
ﬁndings that blockade of IL-10/IL-10R interaction can resolve chronic viral infection and second, we reﬂect on how
neutralization of the chemokine CXCL10 can abrogate virus-induced type 1 diabetes.
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Introduction
Lymphocytic choriomeningitis virus (LCMV) infec-
tion of mice has proven to be one of the most
informative experimental systems for investigating
various aspects of virology and immunology. The
various LCMV models offer several acute and
persistent infection systems that are well suited to
reﬂect immune kinetics asthey might occur inavariety
of human chronic infections. In addition, transgenic
expression of LCMV proteins as model target antigens
in the pancreas or the CNS is being used in animal
models for type 1 diabetes (T1D) (Ohashi et al. 1991;
Oldstone et al. 1991) and multiple sclerosis (MS)
(Evans et al. 1996), respectively.
LCMV belongs to the arena virus family and is a
natural pathogen for both humans and mice (Zinker-
nagel and Doherty 1974). The viral genome is
comprised of two single stranded RNA segments;
both segments are antisense, each encoding two
proteins.Thelarger(L)segmentencodestheLprotein
(the viral polymerase) and the Z protein with an
undeﬁnedfunction.Theshort(S)segmentencodesthe
nucleoprotein (NP) and the glycoprotein (GP), which
undergoes post-translational cleavage to generate the
twomatureGPs,GP1andGP2(BorrowandOldstone
1997). LCMV can cause acute or persistent infection
in vivo depending on the strain, route of infection and
dose. Whereas adult mice inoculated intravenously
with LCMV strain Armstrong (LCMV-Arm) rapidly
clear the infection and remain immune-competent
with the establishment of a stable memory T cell pool
(Figure 1) (Marker and Volkert 1973; Moskophidis
et al. 1987), inoculation with the LCMV variant Cl13,
which differs from its parent (LCMV-Arm) virus at
only one amino acid positions in the virus GP is
associated establishment of a chronic infection. This
chronic infection is associated with both the functional
impairment and deletion of virus-speciﬁc CD8 T cells
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1993; Lin and Welsh 1998).
Chronic-persisting protracted LCMV variant
Clone 13
The LCMV variant Clone 13 (Cl13) was originally
isolated from the spleen of a 2 month old mouse
infected at birth with LCMV-Arm (Matloubian et al.
1990). The molecular basis of persistence and
suppression of the anti-LCMV cytotoxic T lympho-
cyte (CTL) response has been mapped to a single
amino acid change in LCMV-GP; LCMV-Arm has a
phenylalanine at amino acid position 260, whereas the
variantCl13hasaleucineatthisposition(Salvatoetal.
1991; Dockter et al. 1996). Infection of mice with high
doses of Cl13 leads to a persistent infection that is
associated with a lack of viral antigen speciﬁc CD8
effectors (Figure 1) (Moskophidis et al. 1993; Lin and
Welsh 1998).
A peripheral membrane protein, alpha-dystroglycan
(a-DG), was identiﬁed as the receptor for LCMV
(Cao et al. 1998). Additionally, it was observed that
Cl13 binds more strongly to a-DG as compared to the
Armstrong strain (Smelt et al. 2001). The afﬁnity of
the viral binding to its receptor might be a crucial
element in determining the outcome of infection with
LCMV Armstrong (lower afﬁnity to a-DG) versus
Cl13 (high afﬁnity to a-DG). It was shown that
differences in binding afﬁnities of LCMV strains to
a-DGcorrelatedwithviraltropismanddiseasekinetics
(Smelt et al. 2001). LCMV-Arm and Cl13 appear to
exhibit differences in their tropism within the spleen,
with Cl13 causing a higher level of infection of antigen
presenting cells (APCs) in the white pulp, including
periarterial interdigitating DCs. Cl13 could thereby
render these cells targets for more effective destruction
by the antiviral CD8
þ CTL response which is induced
at an early time point following infection with Cl13
compared to LCMV-Arm. As a consequence this
CD8-dependent destruction of dendritic cells (DCs)
inthespleenofCl13-infectedmiceleadstotheensuing
immunosuppression (Borrow et al. 1995). In vitro
studies showing a decline of DCs after infection with
Cl13 but not LCMV-Arm support the notion that the
loss was related to infection (Sevilla et al. 2004).
Additionally, it was reported that DCs obtained from
cultures infected with Cl13, but not LCMV-Arm were
non-functional, as demonstrated by their ability to
stimulate allogeneic T cells (Sevilla et al. 2004).
Interestingly, upon closer look, this publication
also shows that the loss of DCs was mostly restricted
to the CD11c þ CD8a
þ population and affected
CD11c þ CD8a
neg DCs to a much lesser extent.
IL-10 as a modulator of APC function
Interleukin-10 (IL-10) is an immunosuppressive
cytokine with implications for various immune and
inﬂammatory diseases. It inhibits a broad spectrum of
cellular immune responses, acting on APCs by, i.e.
preventing DC maturation and thereby keeps the
cells in an immature state and T cells by inhibiting
pro-inﬂammatory cytokine production. Investigations
have revealed that IL-10 play important roles in
blocking cytokines production (Fiorentino et al. 1991)
costimulatory molecules expression, there under
MHC class II, CD80 and CD86 (Ding et al. 1993;
Willems et al. 1994) as well as chemokine secretion
( J i n q u a ne ta l .1 9 9 3 ;K a s a m ae ta l .1 9 9 4 )
and modiﬁcation of chemokine receptor expression
(Sozzani et al. 1998; Takayama et al. 2001) (for review
see Pestka et al. 2004). Apart from the reported potent
immune-modulatory effects on APCs, IL-10 also
affects TH1- and TH2-type immune responses, as
evidenced by ﬁndings in asthma, transplantation
and autoimmunity models (Moore et al. 2001).
IL-10 regulates the proliferation and differentiation
of TH1-type T lymphocytes, which appear to control
many effector immune responses (i.e. host defense,
anti-tumor immunity, autoimmunity) in vivo
(Fiorentino et al. 1991). In different cell types, the
duration of stimulation affects IL-10 expression
differentially. In T cells IL-10 expression occurs
shortly after stimulation and the levels of IL-10
Figure 1. Mice infected with medium dose LCMV Armstrong
develop an acute viral infection characterized by an initial expansion
of anti-viral speciﬁc T CD8 þ cells (blue line) with the ability to
efﬁciently eliminate virus infected target. During their expansion,
viral antigen-speciﬁc CD8
þT cells acquire effector functions,
including the ability to rapidly produce cytokines. Viral clearance
is dependent on the presence of CD8
þ virus-speciﬁc CTLs
(Zinkernagel and Welsh 1976; Oldstone et al. 1986; Jamieson et al.
1987; Moskophidis et al. 1987); and the infection is cleared by day
10–12 from blood and spleen (Blue shaded area). After expansion
of effectors and their contraction, a stable memory CD8
þT cell
population is generated that can be maintained in the absence of
antigen (blue line) (Lau et al. 1994; Murali-Krishna et al. 1999;
Homann et al. 2001; Kaech et al. 2002). In contrast, infection with
Cl13, results in a prolonged infection that persists (red shaded area).
This chronic infection is associated with both the functional
impairment,deletion ofvirus-speciﬁc CD8T cells anddue to lack of
establishment of a memory T cells pool inability mount sufﬁcient
recall responses (red line).
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2002). Elevated levels of IL-10 mRNA have been
observed in immune-responsive versus non-respon-
sive metastatic melanoma lesions (Mocellin et al.
2001). Moreover, treatment with a combination of
anti-IL-10 receptor (IL-10R) monoclonal antibody
(mAb) and toll-like receptor 9 (TLR9) ligands has
been shown to have potent therapeutic anti-tumor
effects (Vicari et al. 2002; Vicari and Trinchieri 2004),
pointing to the role of IL-10 in the development of
cancer. Furthermore, IL-10 has also been shown to
play a role in the establishment of certain chronic viral
infections such as human immunodeﬁciency virus
(HIV-1) (Granelli-Piperno et al. 2004), hepatitis C
(HCV) and human cytomegalovirus (HCMV) infec-
tions (Rigopoulou et al. 2005). Interestingly, an
increase in systemic IL-10 production has been
demonstrated upon HCV infection (Accapezzato
et al. 2004), and in some cases of infection with HIV
(Akridge et al. 1994; Ameglio et al. 1994; Autran et al.
1995; Granelli-Piperno et al. 2004; Ji et al. 2005).
Current immunotherapeutic approaches
in persistent infections
As the hallmark of chronic infection is an impaired
virus speciﬁc effector cell response, numerous efforts
have been undertaken to increase anti-LCMV
immunity. Conventional immunotherapy attempting
to augment anti-viral immunity directly in persistent
infected individuals has failed to affect the outcome
so far, but lowering the viral antigenic load
(by interferons or anti-viral drugs) has clear beneﬁcial
effects. Additionally, speciﬁc immunization strategies
have been combined with direct anti-viral drug
treatments, for example protease inhibitors and highly
active antiretroviral therapy (HAART) in HIV (Palella
et al. 1998) and interferon administration, and
ribavirin in hepatitis infections (Torriani et al. 2004;
Kamar et al. 2005). In all of the situations where anti-
viral drugs were employed, viral loads were signiﬁ-
cantly reduced and, for HIV, long-term deleterious
consequences of the persistent infection were
decreased. Interestingly, the outcome of ribavirin
administration in chronic HCV was not quite as
promising, although viral titers were lowered, since
liver ﬁbrosis was enhanced, possibly as a rather direct
effect of the drug (Torriani et al. 2004; Kamar et al.
2005). However, complete elimination of the patho-
gen has remained elusive, despite the fact that anti-
viral immunity was signiﬁcantly increased in many
instances.
Much attention has been paid to the role if IL-10 as
a potent anti-inﬂammatory immuno-suppressive
cytokine with important potential clinical appli-
cations. So far it remains unclear, whether IL-10
affects the outcome of infection, amount of immuno-
pathology and complications and could be the actual
cause for persistence. One major concern in clinically
manipulating the levels of IL-10 is its critical role in
the immune homeostasis. Long-term application of
IL-10 could cause immunodeﬁciency, whereas con-
tinuous use of anti-IL-10 may lead to hyper immune
reactivation. However, blocking the cytokine receptor
itself for a short period of time is a relative novel
approach to control the signaling effects of the
cytokine. To gain further insight into the function of
IL-10 in the establishment and maintenance of
persistent viral infections, we have investigated how
blockade of the IL-10/IL-10 receptor signaling path-
way affects LCMV chronic infection in its natural
host, the mouse.
Neutralization of IL-10 resolves chronic viral
infection
LCMV Cl13-infection results in a prolonged period of
elevated IL-10 production, which is predominantly
produced by CD4 þ T cells already early upon
infection (Ejrnaes et al. 2006). This interestingly
coincides with the loss of the systemic CTL response
against the virus. Treatment with a neutralizing
IL-10R antibody that was previously shown to block
IL-10/IL-10R interaction in vitro (BD Biosciences)
results in accelerated viral clearance (Ejrnaes et al.
2006). This is associated with a numeric increase of
total spleen cells in comparison to non-treated mice
indicating that development of lymphopenia is
reversed upon anti-IL10R mAb treatment (Ejrnaes
et al. 2006). Furthermore, this rapid resolution of viral
infection is associated with diminished levels of
endogenous IL-10 and enhanced anti-viral CD8
þ
memory T cell responses (Ejrnaes et al. 2006).
Importantly, overall clinical appearance is improved
through such an intervention as reﬂected in an
increase in bodyweight, healthy shiny coat, and
increase in physical activity (Ejrnaes et al. 2006).
Interestingly, this protection from chronic infection
was achieved with only a few injections of neutralizing
anti-IL-10R mAb immediately after virus infection.
Thus, the duration of treatment could be minimized
in order to avoid long-term systemic immunosuppres-
sive effects.
Previous reports suggest that different DC subsets
vary in their ability to prime effector T cells (Liu
2001), and in particular, evidence suggests that DCs
can be converted to APCs, which skew the immune
response towards TH2-domination, when treated with
anti-inﬂammatory cytokines such as IL-10 (Buelens
et al. 1995; Liu 2001). In this context we found that
activation of LCMV-speciﬁc T cells in chronically
infected mice is preferentially achieved by CD8a
2
DCs, which induced IL-10 production by virus-
speciﬁc CD4
þT cells (Ejrnaes et al. 2006). Subclasses
of DCs have been shown to have the potential
to differentially skew cytokine production towards
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Notably, it has been suggested that CD8a
2 DCs
induce TH2-proﬁles whereas CD8a
þ DCs preferen-
tially stimulate IFN-g production and therefore
induce TH1 proﬁles (Maldonado-Lopez et al. 1999),
a result we could conﬁrm when analyzing the ability of
CD8a
þ and CD8a
2 DCs to polarize naı ¨ve LCMV-
reactive CD4
þT cells (Ejrnaes et al. 2006). The
generalized state of lymphopenia induced by Cl13
infection might be mediated by APCs inducing IL-10
production. However, the mechanisms by which IL-
10 enables Cl13 to persist are unknown. IL-10 could
either down-regulate pro-inﬂammatory responses in a
general manner or, more speciﬁcally, inhibit the
induction or expansion of anti-viral CTLs. In fact, IL-
10 may directly decrease the viability of CD8a
þ DCs
as has been previously suggested (Maldonado-Lopez
et al. 2001; Re and Strominger 2004). In the state of
chronic Cl13 infection, prominent CD8a
2 DCs with
reduced ability to prime TH1/TC1 effectors “by
default” become the modulators of the T cell response
and thus derail anti-LCMV immunity through the
production of IL-10 (Figure 2). While the precise
mode of action of IL-10 is unknown, LCMV-speciﬁc
CD4
þT-cells activated in this context may in turn
acquire the ability to produce IL-10 and provide
inappropriate or insufﬁcient anti-viral help to other
cell types, in particular CD8
þT cells, thus leading to
persistent infection (Figure 2). Additionally, it is
possible that the remaining CD8a
2 DCs, which
appear ill-equipped to propagate anti-viral effectors,
will continue to support IL-10 production. The
resulting high concentration of IL-10 in the milieu
may thus lead to further modulation of DC function
and in this way become a self-fulﬁlling phenomenon
(Figure 2). As a consequence, only disruption ofIL-10
signaling will have the ability to break this vicious
circle and enable the recovery of appropriate anti-viral
immunity by the infected host. Since blockade of
IL-10 signaling likely directly acts on DCs, a central
switch in immunity could be implanted in this way
directly at the core, where most immune responses are
orchestrated.
Virus-induced type 1 diabetes
Another possible consequence of virus infection and
its accompanying inﬂammatory cascades is the
initiation or acceleration of autoimmune disease.
One scenario that might be involved in the etiology of
autoimmune disease is that virus infection could break
self-tolerance due to an inherent structural similarity
to self-components (Oldstone 1989; Cantor 2000;
Olson et al. 2001; Miller et al. 2001; Christen and
Herrath 2004; Christen et al. 2004b). This concept of
molecular mimicry has been integrated into animal
models for various human autoimmune diseases such
as T1D, MS, or systemic lupus erythematosus (SLE)
(for review see Christen and von Herrath 2004a). The
RIP-LCMV mouse model for T1D that was estab-
lished in 1991 in the laboratories of Michael Oldstone
(Oldstone et al. 1991) and Rolf Zinkernagel (Ohashi
et al. 1991). These mice express the GP or NP of
LCMV-Arm in the insulin-producing beta-cells of the
islets of Langerhans in the pancreas. Such beta-cells
are the target of the auto-aggressive immune system in
T1D. Since the transgenically expressed viral protein
is considered a component of “self”, RIP-LCMV mice
Figure 2. LCMV Cl13 persistence is the result of an early CTL-mediated loss of CD8a
þ DCs, which indirectly supports immune responses
high in IL-10 production that might be predominantly driven by the remaining CD8a
neg CD11c
þ DCs.
M. Ejrnaes et al. 340are tolerant and do not mount an immune response
to the LCMV protein. However, infection with
LCMV-Arm itself breaks this self-tolerance, auto-
aggressive LCMV-speciﬁc T cells are generated and
expanded, the beta-cells are being destroyed and
ultimately clinical overt diabetes results (Figure 3). In
the context of this review article it is important to
reiterate here that LCMV-Arm is one of the isolated
LCMV strain that has no immunosuppressive proper-
ties and does not result in persistent infection. In the
past this model was used to investigate mechanisms
of how autoimmune processes are involved in the
pathogenesis of T1D and to evaluate possible
treatments for human T1D in an animal model.
Just as proposed for human T1D, the onset
of diabetes in RIP-LCMV mice depends on the action
of both, autoreactive CD4 and CD8 T-cells and
correlates with the numbers of auto-aggressive
lymphocytes generated. In accordance, the incidence
of disease varied between the individual transgenic
lines ranging from 2 weeks (RIP-GP lines) to 1–6
months (RIP-NP lines). Further studies revealed
the mechanism involved in the rapid compared to the
slow onset diabetes: Transgenic lines expressing the
LCMV-GP transgene exclusively in the b-cells of
the islets manifested rapid-onset T1D (10–14 days
after viral challenge) (von Herrath et al. 1994). In
these lines the high systemic numbers of auto-
aggressive CD8 T-cells were sufﬁcient to induce
diabetes and did not require help from CD4 cells. In
contrast, in lines expressing the LCMV-NP transgene
in both the b-cells and in the thymus, T1D took longer
to occur after subsequent LCMV challenge. Several
lines of evidence indicated that in RIP-NP mice the
anti-self (viral) CTL were of lower afﬁnity and that
CD4 T-cells were essential to generate anti-self (viral)
CD8 lymphocyte-mediated T1D (von Herrath et al.
1994). In addition, mouse models in which transgene-
encoded “target-antigens” are expressed in the
pancreatic b-cells, such as the RIP-LCMV and
the INS-HA (Lo et al. 1992; Lo et al. 1993) mouse,
have demonstrated that the presence of auto-
aggressive T-cells alone is not enough to cause disease.
For example, when RIP-LCMV mice were crossed
Figure 3. Therapeutic intervention during the ongoing destruction of islet cells in the pancreas.—After LCMV infection active virus is
found in the pancreas but not necessarily in the islets. In an initial stage local resident macrophages or dendritic cells are activated and release
pro-inﬂammatory cytokines, such as TNFa. Blocking of TNFa at this early stage after infection can abrogate T1D (Christen et al. 2001;
Christen and von Herrath 2004c) (panel B). Chemokines, most prominently CXCL10, are released by endothelial cells and b-cells (Frigerio
et al. 2002; Christen et al. 2003) (panel C) which in turn attract islet-speciﬁc auto-aggressive T lymphocytes as well as non-speciﬁc bystander
cells into the islets of Langerhans (Christen et al. 2003; Rhode et al. 2005) (panel D). At that time neutralization of CXCL10 prevents the
subsequent development of T1D by interfering with the migration of auto-aggressive T lymphocytes to the pancreas (Christen et al. 2003).
When not prevented from doing so, the ﬁrst islet-speciﬁc auto-aggressive CD8 cells destroy some b-cells by perforin dependent cytolysis
resulting in release of b-cell antigens (panel E). These antigens include transgenic viral proteins and additional non-viral components and are
processed and presented to inﬁltrated CD8 and CD4 cells by APC (panel E). In the terminal stage of immunopathogenesis the majority of
b-cells are being destroyed by auto-aggressive CD8 cells in a IFNg dependent manner (Seewaldt et al. 2000). It is only in this ﬁnal stage where
clinicallyovert diabetes is apparent and can be assessed by blood glucose measurements. The destructive process at this end stage can however
be reversed in the presence of high local concentrations of TNFa (islet-speciﬁc TNFa expression in a transgenic system) which can induce a
status of hyper-activation resulting in apoptosis of auto-aggressive CD8 (Christen et al. 2001; Christen and Von Herrath 2002) (panels D and
E). Similarly, expression of CXCL10 at an auxiliary site, such as the PDLN, can cause a recruitment of auto-aggressive CD8 cells away from
the islets and a subsequent apoptosis in the PDLN by hyper-activation (Rhode et al. 2005).
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IFNgR the diabetes incidence was drastically reduced
(Seewaldt et al. 2000). These results indicate that
unspeciﬁc “bystander factors”, such as cytokines
and chemokines generated during the acute inﬂamma-
tion after LCMV infection, are important to drive
the auto-aggressive response (b-cell destruction) in
“antigen-speciﬁc” models for T1D.
Hence, the RIP-LCMV model has become a very
useful tool to study the etiology and the mechanisms
of human autoimmune diabetes and to evaluate
possible treatments, such as blockade of speciﬁc
inﬂammatory factors, as discussed below (Christen
et al. 2001; Christen et al. 2003), oral tolerance
induction (Homann et al. 1999) or DNA-vaccination
(Coon et al. 1999). Besides having a clearly deﬁned
initiation point (LCMV-infection), the advantage of
the RIP-LCMV system over other established models
for T1D, such as the NOD mouse, is the presence of
extensively characterized target antigens (GP, NP).
The immune response against these target antigens
can be visualized using ﬂow cytometry by stimulation
of splenocytes with LCMV-peptides or direct staining
of CD8 T-cells with MHC class (-peptide tetramers
(Murali-Krishna et al. 1998). In addition, we recently
demonstrated tracking of LCMV-speciﬁc CD8 T-cells
by in situ MHC class (-peptide staining of quick-frozen
tissue sections (McGavern et al. 2002).
CXCL10—a sentinel chemokine during
inﬂammation
Among the inﬂammatory mediators generated upon
LCMV-infection of the pancreas, CXCL10 proved to
play a key role in imprinting a pattern for the
subsequent development of autoimmune disease in
the RIP-LCMV model. In general, ligands of the
CXCR3 chemokine receptor including CXCL10
(interferon-induced protein of 10kDa, IP-10),
CXCL9 (monokine induced by gamma-interferon,
Mig), and CXCL11 (interferon-inducible T-cell a
chemoattractant, I-TAC) have been suggested to play
an essential role during inﬂammation and auto-
immunity. CXCR3 chemokine ligands are mainly
expressed by keratinocytes, macrophages, ﬁbroblasts,
and endothelial cells upon stimulation with IFNg or
TNFa (Luster et al. 1985; Luster and Ravetch 1987)
but are also generated by activated T-cell hybridomas,
normal T-cells, and thymocytes (Gattass et al. 1994).
CXCL10 was suggested to function as a “sentinel
molecule” in host defense against viruses (Liu et al.
2000) and is generated very early after infection with a
wide variety of viruses such as HIV, adenovirus,
LCMV, Theiler’s virus and mouse hepatitis virus
(Asensio and Campbell 1997; Lane et al. 1998;
Charles et al. 1999; Hoffman et al. 1999; Kolb et al.
1999). Further, CXCR3 chemokine ligands are have
been implicated in the host defense against foreign
pathogens by promoting local inﬂammation. Blockade
of CXCL10 disturbed the control of parasite
propagation after Toxoplasma gondii infection by
abrogating T-cell migration into tissues and impairing
antigen-speciﬁc T-cell function resulting in ampliﬁed
tissue parasite burden and an increased mortality
(Khan et al. 2000). Further, transgenic (tg) CXCL10
expression in keratinocytes resulted in delayed wound
healing and disorganized neo-vascularization due to a
more intense inﬂammatory phase (Luster et al. 1998).
CXCR3 is the only cellular receptor for CXCL9,
CXCL10 and CXCL11 identiﬁed to date, and is
predominantly found on activated Th1-type T-cells
(Loetscher et al. 1996; Sallusto et al. 1998). Thus,
CXCR3 chemokines direct the anti-viral defense
towards the more aggressive type 1 T-cell-domination
and act as “bystander effectors” that unspeciﬁcally
activate T-cells (including autoreactive T-cells) and
subsequently drive an auto-aggressive immune
response that may result in autoimmune disease.
Unique role of CXCL10 in imprinting a pattern
for autoimmune disease
Data from our lab suggest that, among CXCR3
chemokines, CXCL10 plays a unique role in imprint-
ing a pattern for the subsequent development of
autoimmunity (Christen et al. 2003; Christen and von
Herrath 2004b). As previously reported for infection
of the CNS by various viruses (Asensio and Campbell
1997; Lane et al. 1998; Charles et al. 1999; Hoffman
et al. 1999; Kolb et al. 1999), infection of mice with
LCMV caused a very rapid and strong expression
of CXCL10 in the pancreas (Christen et al. 2003).
Interestingly, CXCL10 was the only chemokine
whose expression was strongly induced as early
as 1 day after infection. The other two CXCR3
chemokine ligands were either expressed later
(CXCL9) or were only faintly upregulated
(CXCL11). Further, chemokines such as CCL3
(MIP-1a) or CCL5 (RANTES) were not increased
until day 7 post-infection, a time where most pro-
inﬂammatory cytokines including TNFa, and IFNg
are strongly expressed as well (Christen et al. 2003).
Very recently, the important role of CXCL10
during virus-induced diabetes was underlined in
RIP-CXCL10 transgenic mice, which showed a
spontaneous inﬁltration of islets by a mixed leukocyte
population (Rhode et al. 2005). These mice were not
diabetic but had a reduced capacity to response to a
high glucose challenge possibly due to “inﬂammatory
stress” to the islets (Rhode et al. 2005). In addition,
when crossed to the RIP-LCMV mouse line the
RIP-CXCL10 mice had accelerated T1D after
infection with LCMV (Rhode et al. 2005). Thus,
CXCL10 is a prime candidate for a neutralization
attempt to rescue mice from autoimmune disease.
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diabetes
We used a very characterized neutralizing monoclonal
antibody to CXCL10 that was previously shown to
block the biological activity of CXCL10 Toxoplasma
gondii infection model (Khan et al. 2000). Brieﬂy,
neutralization of CXCL10 inhibited the inﬂux of
activated T-cells into tissue and a 1000-fold higher
parasite burden resulting in a higher mortality of
infected mice (Khan et al. 2000). In our T1D mouse
model we found that indeed blockade of CXCL10
with this neutralizing antibody abrogated disease in
.60% of all LCMV-infected mice (Christen et al.
2003). In contrast blockade of CXCL9 with a
neutralizing anti-CXCL9 antibody neither reduced
the incidence nor prolonged the onset of diabetes
(Christen et al. 2003). Mechanistically, blockade of
CXCL10 interfered with the expansion of LCMV-
speciﬁc auto-aggressive CD8 T-cells and their
migration to the pancreatic islets of Langerhans
(Christen et al. 2003). Thus, neutralization of one
critical inﬂammatory factor at the right time could
prevent the subsequent development of autoimmune
disease. It is important here to note, that the treatment
had to be administered at the precise time when
CXCL10 was expressed at high density. Rescued mice
received ﬁve intravenous injections of 100mg
neutralizing antibody at days 0, 1, 2, 4 and 6 post
infection. Treatment of mice before LCMV-infection
or at a later time (days 7–14) was not successful in
preventing autoimmune disease (U.CH. unpublished
observations and reference (Christen et al. 2003)).
The same monoclonal anti-CXCL10 antibody was
used to neutralize CXCL10 in the CNS of mice with
experimental autoimmune encephalomyelitis (EAE)
(Fife et al. 2001). Similar to our experiences in the
RIP-LCMV model, CXCL10 neutralization
decreased the accumulation of antigen-speciﬁc lym-
phocytes to the site of autoimmune damage (Fife et al.
2001). A different approach to neutralize CXCL10
was recently published by the Narumi group who
made use of the non-obese diabetic (NOD) mouse
model for spontaneous T1D (Morimoto et al. 2004).
They administrated young NOD mice with a DNA
plasmid encoding CXCL10. This DNA vaccination
approach resulted in the in vivo generation of
neutralizing anti-CXCL10 antibodies and suppressed
the development of diabetes (Morimoto et al. 2004).
In contrast to the ﬁndings in the RIP-LCMV model,
the treatment did neither reduce insulitis nor alter the
islet-speciﬁc immune response. It rather enhanced the
proliferation of the insulin-producing b-cells resulting
in a higher b-cell mass (Morimoto et al. 2004).
Another interpretation of these data would be that
CXCL10 neutralization relieves the islets from
“inﬂammatory stress”. Thus, b-cells from DNA-
vaccinated NOD mice might proliferate at a normal
rate whereas b-cells from untreated NOD mice show
reduced proliferation rates and therefore insufﬁcient
insulin production. However, the experiments by
Morimoto et al demonstrate that neutralization of
CXCL10 can be successful even in a spontaneous
model such as the NOD mouse.
It was previously demonstrated that CXCL10
is predominantlyexpressed byb-cells upon LCMV-in-
fection of the pancreas (Frigerio et al. 2002; Rhode
etal.2005).However,recentobservationsinourgroup
showthatdiabetogenicT-cellclonesproduceCXCL10
as well (Ejrnaes et al. 2005). In this study, CD8 T-cell
clones speciﬁc for the islet antigens insulin, glutamic
acid decarboxylase (GAD) and LCMV-GP were
analysed for expression of various chemokines and
cytokines. Interestingly, there was a clear correlation
between diabetogenicity and the expression of
CXCL10 (Ejrnaes et al. 2005). Additional CXCL10-
expression by auto-aggressive T-cells might lead to a
perpetuated inﬁltration rate of the islets and sub-
sequent acceleration of the destructive process.
Auxiliary CXCL10 expression can abrogate
autoimmune disease
Whereas expression of CXCL10 at the site of
autoimmune damage clearly accelerates the immuno-
pathogenic process and exacerbates disease (Rhode
et al. 2005), auxiliary expression of CXCL10 can,
under certain circumstances, abrogate the ongoing
autoimmune destruction. In the late 1980ies it was
observed that infection of NOD mice with LCMV can
be used as a therapeutic intervention to prevent T1D
(Oldstone 1988; Oldstone 1990). In the RIP-LCMV
model T1D could be abrogated by a secondary
infection with one particular strain of LCMV (strain
Pasteur, LCMV-Past) but not with LCMV-Arm
(strain Armstrong) that was used for the initial
induction of disease (Christen et al. 2004a). The
major difference between those two LCMV strains,
that share all the immunologically relevant epitopes, is
a striking discrepancy in viral growth in the pancreatic
draining lymph node (PDLN). Secondary infection
with LCMV-Past resulted in higher viral titers in the
PDLNwhencomparedtothepancreasandtoinfection
with LCMV-Arm. Along with this augmented viral
proliferation a differential expression of the inﬂamma-
tory chemokine CXCL10 between PDLN and
pancreas was observed (Christen et al. 2004a).
Interestingly, a similar increase in PDLN-speciﬁc
CXCL10 expression could be detected in NOD mice
infected with LCMV-Past as well as LCMV-Arm
(Christen et al. 2004a). In both LCMV-Past-infected
NOD and RIP-LCMV mice a signiﬁcant decrease in
the inﬁltration of islets and an increase in cellular
apoptosis in the PDLN was detected (Christen et al.
2004a). Apparently, auto-aggressive cells migrated
away from the islets and got stuck in the PDLN due to
Cure of chronic viral infection and virus-induced type 1 diabetes 343the high CXCL10 concentration. Once arrived at the
highly inﬂamed PDLN the cells were hyper-activated
and died by apoptosis. Thus, in such a scenario, the
LCMV-infected, highly inﬂamed auxiliarysite may the
actasaﬁlterforauto-aggressivelymphocytes(Christen
and von Herrath 2005).
Summary
Neutralizing antibodies have been widely used to
interfere with receptor-ligand interactions in vivo.
Blockade of soluble inﬂammatory mediators and/or
their cellular receptors is an highly effective way to
down-regulate inﬂammation or prevent its negative
consequences. In contrast to non-speciﬁc chemical
immunomodulators or systemic treatment with
cytokines, such as IFN-a, which act on a relatively
broad range and thus can cause either unwanted
severe side effects or general immunosuppression
or -activation, neutralizing monoclonal antibodies act
in a more speciﬁc way by preventing the binding of key
mediators of inﬂammation to their cellular receptor.
Nevertheless, long-term systemic administration of
neutralizing antibodies inactivates the function of such
mediators in their natural role in defense against
harmful pathogens, such as viruses. It is therefore
important to design a therapeutic regimen in way to
reach maximal efﬁcacy with a minimal side effects.
This can only be achieved by a detailed knowledge of
the mechanisms of action and the expression kinetics
of such inﬂammatory mediators. In this review we
highlighted two recent ﬁndings from our lab that
demonstrate that short term neutralization of inﬂam-
matory mediators can abrogate or reverse adverse
effects of chronic inﬂammation. First, blockade of
IL-10/IL-10R interaction can resolve chronic viral
infection. Mechanistically, IL-10 neutralization
restores the anti-viral immune response that was
derailed by viral infection of a speciﬁc subgroup of
APCs, namely the CD8a- DCs. Second, short-term
neutralization of CXCL10 after in virus infection
prevented the progression from inﬂammation to
autoimmune disease in a mouse model for T1D. In
both examples, the precise timing and duration of
administration of neutralizing antibodies was critical
for success. Similarly, treatment of LCMV-infected
RIP-LCMV mice with TNFR55-IgG1 fusion protein
to neutralize TNFa was only successful when given
early after infection (Christen et al. 2001). The ﬁnding
that transgenic expression of TNFa early after
infection enhanced the incidence of T1D, whereas
late TNFa-expression reversed the auto-destructive
process, suggested that TNFa has actually a dual role
in T1D depending on the time of its expression
(Christen et al. 2001). Thus, for applications of
neutralizing antibodies as therapeutic agents one has
to consider carefully on one hand the precise timing of
treatment in order to achieved the desired protective
effect and on the other hand the duration of the
treatment to avoid permanent suppression or hyper--
activation of the immune system.
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